Overview

Bioequivalence Study of CJ-30059

Status:
Unknown status

Trial end date:
2014-08-01

Target enrollment:

Participant gender:

Summary

This study is designed to evaluate the bioequivalence of the two treatments, the administration of CJ-30059 and the co-administration of candesartan cilexetil and amlodipine besylate, in healthy volunteers.

Phase:

Phase 1

Details

Lead Sponsor:

CJ HealthCare Corporation
HK inno.N Corporation

Treatments:

Amlodipine
Candesartan
Candesartan cilexetil